HEPH and plasma cell myeloma: Mzb has been shown to irreversibly inhibit all three proteasome active sites (CT-L, T-L, and CP-L) in multiple myeloma and in solid tumors 8, 12, thus has increased potency to be a multisite antagonist of the proteasome complex compared to other peptide-based proteasome inhibitors.